BARCELONA—In patients with previously irradiated locally recurrent prostate cancer, salvage high-dose-rate brachytherapy (HDRB) was an effective and safe treatment option. The 3rd ESTRO Forum (April 24-28, 2015) heard data from a retrospective analysis with 60 patients that found HDRB had acceptable late genitourinary toxicity after external beam radiotherapy. Study author Manuel Galdeano Rubio MD from Institut Català d’Oncologia discussed the findings with Oncology Times reporter Sarah Maxwell.
You may also like...
Metastatic renal cell carcinoma: biomarkers to guide future therapy 25 Feb, 2014
Breast Cancer Prognostic Implications of Obesity and Insulin Resistance 28 Mar, 2015
Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer 12 Feb, 2014
Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer 16 Mar, 2013
- Previous story Phase-III Randomized ARCON Trial: Comment from Hans Kaanders
- Next story Accelerated Partial Breast Irradiation for Women over 70 with Early Breast Cancer Improved Outcomes
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014
- First enterovirus 71 vaccines effective against hand, foot and mouth diseaseFebruary 28, 2014